Substance P drives ocular inflammation through the NK-1 receptor, and blocking this peptide pathway reduces inflammation, restores immune privilege, and improves clinical outcomes in animal models and human eye diseases.
NK-1R blockade restores immune privilegeInhibiting Substance P or its receptor ameliorates ocular inflammation and improves clinical endpoints including corneal opacity and angiogenesis
What the researchers found
Substance P (SP) mediates neurogenic inflammation in the eye through binding to the neurokinin-1 receptor (NK-1R), which is expressed on nerves, immune cells, and epithelial cells. SP's inflammatory effects include:
- Increased microvascular permeability and vasodilatation
- Plasma extravasation and tissue edema
- Stimulation of macrophages to release interleukins, chemokines, and growth factors
Inhibition of SP activity — through blocking neuropeptide release or using NK-1R antagonists — ameliorates ocular inflammation, restores immune privilege, and improves clinical endpoints including corneal opacity, ocular perforation, and angiogenesis. These effects have been demonstrated in animal models and in human eye diseases.
Why it matters
Inflammatory eye diseases can cause severe vision loss, and current treatments often rely on broad immunosuppression with significant side effects. Targeting Substance P specifically could provide a more precise anti-inflammatory approach with fewer systemic effects. Understanding this neuropeptide's role also reveals how the nervous system directly contributes to eye inflammation.
How the study worked
This is a literature review summarizing published research on Substance P's role in ocular inflammation, with emphasis on the ocular surface. The review covers the molecular mechanisms of SP-mediated inflammation, evidence from animal models, and therapeutic applications of SP blockade in human eye diseases.
What this study cannot tell us
As a review article, no new experimental data is presented. The evidence varies in quality across the animal models and human studies reviewed. The exact clinical efficacy, optimal dosing, and safety profile of SP inhibitors specifically for ocular use in humans require further investigation through clinical trials.
How to read the evidence
This is a narrative review of published literature spanning animal models and human clinical observations. It synthesizes existing evidence but does not present new data or follow systematic review methodology.
When this study was published
Published in 2016, this review covers the foundational evidence for Substance P's role in ocular inflammation. The field has continued to advance since publication, but the core mechanisms described remain current.
The bigger picture
Substance P is one of the most studied neuropeptides in inflammation research, with roles throughout the body. This review highlights its specific importance in ocular immunity, where the concept of neurogenic inflammation — the nervous system directly driving inflammatory responses — is particularly relevant. NK-1R antagonists are already used in other medical fields (e.g., anti-nausea drugs like aprepitant), suggesting potential for repurposing in eye disease.
Questions still open
- Can existing NK-1 receptor antagonists like aprepitant be repurposed as topical eye drops for inflammatory eye conditions?
- How does Substance P interact with other inflammatory neuropeptides like CGRP in the context of eye inflammation?
- Would long-term SP blockade in the eye have negative consequences for corneal nerve function or wound healing?
Common questions
What is Substance P and how does it cause eye inflammation?
Could blocking Substance P treat eye diseases?
Read the original research
Substance P and its Inhibition in Ocular Inflammation.
Current drug targets, 17(11), 1265-74
Citation
Bignami, Fabio; Rama, Paolo; Ferrari, Giulio. (2016). Substance P and its Inhibition in Ocular Inflammation.. Current drug targets, 17(11), 1265-74.